Truvada Generic Won’t Be Blocked on the French market
This week Paris court dismissed the lawsuit filed by the American biopharmaceutical company Gilead Sciences. Gilead claimed to keep patent on the antiviral drug Truvada and attempted to block the entry of the generic emtricitabine / tenofovir combination to the French market.
In July the data of the Gilead patent for "Truvada" in France expired, and some foreign media sources reported that PrEP might become more available by entering the market for generic company Mylan.
Gilead stated that “where the laboratory has supplementary protection Certificates (PPC) are valid, it extends our intellectual property rights until 2020 “. France is one of the 12 countries under the ambit of this provision, which allows you to bypass the maximum limit of the patent, established 20 years. Get excited about immediately would be premature, as sivertimes.com reported.
It was also reported that 3 more companies (Biogaran, EG and Zentiva) expect to release their products and as well as Mylan,these companies have permission to produce the generic "Truvada."
The similar situation with Truvada is in Germany. On August 17, the Munich court rejected Gilead Sciences to block the entry to the German market of 7 generics of Hexal, Betapharm, Hormosan, Zentiva, Aliud, TAD and Mylan. According to the portal DAZ.online, the price for some of them is lower than the cost of the original by more than 25%. According to the statistics only in the last year Gilead earned over $ 3.5 billion on sales of Truvada, making the drug the best-selling drug for HIV.